These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 9470830

  • 1. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group.
    Thürlimann B, Paridaens R, Serin D, Bonneterre J, Roché H, Murray R, di Salle E, Lanzalone S, Zurlo MG, Piscitelli G.
    Eur J Cancer; 1997 Oct; 33(11):1767-73. PubMed ID: 9470830
    [Abstract] [Full Text] [Related]

  • 2. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
    Clemett D, Lamb HM.
    Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
    [Abstract] [Full Text] [Related]

  • 3. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.
    Kvinnsland S, Anker G, Dirix LY, Bonneterre J, Prove AM, Wilking N, Lobelle JP, Mariani O, di Salle E, Polli A, Massimini G.
    Eur J Cancer; 2000 May; 36(8):976-82. PubMed ID: 10885600
    [Abstract] [Full Text] [Related]

  • 4. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
    Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M, Buzzi F, Bodrogi I, Ludwig H, Reichardt P, O'Higgins N, Romieu G, Friederich P, Lassus M.
    Ann Oncol; 1998 Jun; 9(6):639-45. PubMed ID: 9681078
    [Abstract] [Full Text] [Related]

  • 5. Sequential treatment with exemestane and non-steroidal aromatase inhibitors in advanced breast cancer.
    Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglione F, Pepi F, Fusco O, Del Mastro L, Leonard RC.
    Oncology; 2005 Jun; 69(6):471-7. PubMed ID: 16410685
    [Abstract] [Full Text] [Related]

  • 6. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
    Llombart-Cussac A, Ruiz A, Antón A, Barnadas A, Antolín S, Alés-Martínez JE, Alvarez I, Andrés R, García Saenz JA, Lao J, Carrasco E, Cámara C, Casas I, Martín M.
    Cancer; 2012 Jan 01; 118(1):241-7. PubMed ID: 21717449
    [Abstract] [Full Text] [Related]

  • 7. Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
    Russell CA, Green SJ, O'Sullivan J, Hynes HE, Budd GT, Congdon JE, Martino S, Osborne CK.
    J Clin Oncol; 1997 Jul 01; 15(7):2494-501. PubMed ID: 9215817
    [Abstract] [Full Text] [Related]

  • 8. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.
    Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, Honig S, Polli A, Whaley F, di Salle E, Tiffany J, Consonni A, Miller L.
    J Clin Oncol; 1999 Nov 01; 17(11):3418-25. PubMed ID: 10550136
    [Abstract] [Full Text] [Related]

  • 9. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
    Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H.
    J Clin Oncol; 2003 Mar 15; 21(6):984-90. PubMed ID: 12637461
    [Abstract] [Full Text] [Related]

  • 10. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S.
    Am J Clin Oncol; 2010 Jun 15; 33(3):314-9. PubMed ID: 19730353
    [Abstract] [Full Text] [Related]

  • 11. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.
    Paridaens R, Dirix L, Lohrisch C, Beex L, Nooij M, Cameron D, Biganzoli L, Cufer T, Duchateau L, Hamilton A, Lobelle JP, Piccart M, European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC).
    Ann Oncol; 2003 Sep 15; 14(9):1391-8. PubMed ID: 12954578
    [Abstract] [Full Text] [Related]

  • 12. Combined endocrine treatment of elderly postmenopausal patients with metastatic breast cancer. A randomized trial of tamoxifen vs. tamoxifen + aminoglutethimide and hydrocortisone and tamoxifen + fluoxymesterone in women above 65 years of age.
    Rose C, Kamby C, Mouridsen HT, Andersson M, Bastholt L, Møller KA, Andersen J, Munkholm P, Dombernowsky P, Christensen IJ.
    Breast Cancer Res Treat; 2000 May 15; 61(2):103-10. PubMed ID: 10942095
    [Abstract] [Full Text] [Related]

  • 13. Exemestane: new preparation. No tangible advance in metastatic breast cancer after tamoxifen failure.
    Prescrire Int; 2001 Aug 15; 10(54):108-9. PubMed ID: 11718178
    [Abstract] [Full Text] [Related]

  • 14. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
    Love RR, Hutson PR, Havighurst TC, Cleary JF.
    Clin Cancer Res; 2005 Feb 15; 11(4):1500-3. PubMed ID: 15746052
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
    Tesch H, Stoetzer O, Decker T, Kurbacher CM, Marmé F, Schneeweiss A, Mundhenke C, Distelrath A, Fasching PA, Lux MP, Lüftner D, Hadji P, Janni W, Muth M, Kreuzeder J, Quiering C, Taran FA.
    Int J Cancer; 2019 Feb 15; 144(4):877-885. PubMed ID: 29992557
    [Abstract] [Full Text] [Related]

  • 16. A prospective randomised study of transvaginal ultrasound effects of tamoxifen and exemestane in postmenopausal women with early breast cancer.
    Garrone O, Bertelli G, Principe E, Lewis PD, Occelli M, Miraglio E, Merlano MC.
    Tumori; 2014 Feb 15; 100(6):620-4. PubMed ID: 25688495
    [Abstract] [Full Text] [Related]

  • 17. Exemestane for primary prevention of breast cancer in postmenopausal women.
    Zhang Y, Simondsen K, Kolesar JM.
    Am J Health Syst Pharm; 2012 Aug 15; 69(16):1384-8. PubMed ID: 22855103
    [Abstract] [Full Text] [Related]

  • 18. Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial.
    Schilder CM, Seynaeve C, Beex LV, Boogerd W, Linn SC, Gundy CM, Huizenga HM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB.
    J Clin Oncol; 2010 Mar 10; 28(8):1294-300. PubMed ID: 20142601
    [Abstract] [Full Text] [Related]

  • 19. Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study.
    Mieog JS, Morden JP, Bliss JM, Coombes RC, van de Velde CJ, IES Steering Committee.
    Lancet Oncol; 2012 Apr 10; 13(4):420-32. PubMed ID: 22265698
    [Abstract] [Full Text] [Related]

  • 20. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model.
    Jelovac D, Macedo L, Handratta V, Long BJ, Goloubeva OG, Ingle JN, Brodie AM.
    Clin Cancer Res; 2004 Nov 01; 10(21):7375-81. PubMed ID: 15534114
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.